Compare ATI & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATI | ROIV |
|---|---|---|
| Founded | 1960 | 2014 |
| Country | United States | United Kingdom |
| Employees | 7600 | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6B | 20.7B |
| IPO Year | 1996 | 2021 |
| Metric | ATI | ROIV |
|---|---|---|
| Price | $141.97 | $28.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $124.25 | $27.56 |
| AVG Volume (30 Days) | 2.1M | ★ 4.8M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.76 | N/A |
| EPS | ★ 2.85 | N/A |
| Revenue | ★ $4,043,500,000.00 | $29,053,000.00 |
| Revenue This Year | $9.41 | N/A |
| Revenue Next Year | $8.57 | $385.85 |
| P/E Ratio | $51.32 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $39.23 | $8.73 |
| 52 Week High | $168.14 | $30.33 |
| Indicator | ATI | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 43.96 | 53.51 |
| Support Level | $76.10 | $26.94 |
| Resistance Level | $168.14 | N/A |
| Average True Range (ATR) | 6.38 | 1.01 |
| MACD | -2.86 | -0.21 |
| Stochastic Oscillator | 8.72 | 32.70 |
ATI Inc supplies specialty metals to various end markets, including aerospace and defense, oil and gas, automotive, and electrical energy, among many others. The company's operating segment includes High-Performance Materials and Components and Advanced Alloys and Solutions. The majority of revenue is from the High-Performance Materials segment. The High-Performance Materials segment is focused on a wide range of high-performance specialty materials, parts, and components for several the majority of end markets, including the aerospace & defense, medical, and energy markets. Geographically, it operates in the United States, China, the United Kingdom, Germany, France, Canada, and Others, the majority is from the United States.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.